HPV Prevalence among Women from Appalachia: Results from the CARE Project
Open Access
- 30 August 2013
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (8), e74276
- https://doi.org/10.1371/journal.pone.0074276
Abstract
Cervical cancer incidence and mortality rates are high among women from Appalachia, yet data do not exist on human papillomavirus (HPV) prevalence among these women. We examined the prevalence of genital HPV among Appalachian women and identified correlates of HPV detection. We report data from a case-control study conducted between January 2006 and December 2008 as part of the Community Awareness, Resources, and Education (CARE) Project. We examined HPV prevalence among 1116 women (278 women with abnormal Pap tests at study entry [cases], 838 women with normal Pap tests [controls]) from Appalachian Ohio. Analyses used multivariable logistic regression to identify correlates of HPV detection. The prevalence of HPV was 43.1% for any HPV type, 33.5% for high-risk HPV types, 23.4% for low-risk HPV types, and 12.5% for vaccine-preventable HPV types. Detection of any HPV type was more common among women who were ages 18–26 (OR = 2.09, 95% CI: 1.26–3.50), current smokers (OR = 1.86, 95% CI: 1.26–2.73), had at least five male sexual partners during their lifetime (OR = 2.28, 95% CI: 1.56–3.33), or had multiple male sexual partners during the last year (OR = 1.98, 95% CI: 1.25–3.14). Similar correlates were identified for detection of a high-risk HPV type. HPV was prevalent among Appalachian women, with many women having a high-risk HPV type detected. Results may help explain the high cervical cancer rates observed among Appalachian women and can help inform future cervical cancer prevention efforts in this geographic region.Keywords
This publication has 29 references indexed in Scilit:
- Human Papillomavirus (HPV) 6, 11, 16, and 18 Prevalence Among Females in the United States—National Health and Nutrition Examination Survey, 2003–2006: Opportunity to Measure HPV Vaccine Impact?The Journal of Infectious Diseases, 2011
- Prevalence of Genital Human Papillomavirus Among Females in the United States, the National Health and Nutrition Examination Survey, 2003–2006The Journal of Infectious Diseases, 2011
- U.S. Geographic Distribution of Prevaccine Era Cervical Cancer Screening, Incidence, Stage, and MortalityCancer Epidemiology, Biomarkers & Prevention, 2011
- Psychosocial predictors of adherence to risk-appropriate cervical cancer screening guidelines: A cross sectional study of women in Ohio Appalachia participating in the Community Awareness Resources and Education (CARE) projectPreventive Medicine, 2010
- Measuring cervical cancer risk: development and validation of the CARE Risky Sexual Behavior IndexCancer Causes & Control, 2009
- Acceptance of the HPV vaccine among women, parents, community leaders, and healthcare providers in Ohio AppalachiaVaccine, 2009
- Human papillomavirus (HPV) vaccine availability, recommendations, cost, and policies among health departments in seven Appalachian statesVaccine, 2009
- A review of human carcinogens—Part B: biological agentsThe Lancet Oncology, 2009
- Prevalence of High-Risk Human Papillomavirus Among Older WomenObstetrics & Gynecology, 2008
- Chapter 6: Epidemiology and transmission dynamics of genital HPV infectionVaccine, 2006